Diclosin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diclosin

Property Description
Active ingredient Diclofenac (e.g., Sodium or Potassium salt)
Forms Oral tablet, topical gel, injectable solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Relief from pain, inflammation, and fever
Origin Synthetic (Phenylacetic acid derivative)

1. Diclosin: Definition and Pharmacological Classification

Diclosin is a synthetic pharmaceutical product containing the active compound Diclofenac, which is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Chemically, Diclofenac belongs to the group of phenylacetic acid derivatives, and it is frequently supplied as a pharmaceutical salt, such as Diclofenac Sodium.

Its fundamental classification as an NSAID confirms that the medication possesses combined anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) effects. The compound is utilized as an agent for managing discomfort and is a standard choice for conditions involving swelling and pain.

2. Composition and General Therapeutic Purpose

The medicinal effect of Diclosin is driven by the action of Diclofenac. The general therapeutic purpose of the medicine is to alleviate discomfort by interrupting the biological processes that cause pain and inflammation.

This relief is achieved because Diclofenac is an inhibitor of cyclooxygenase (COX) enzymes, thereby reducing the body’s production of lipid signaling molecules known as prostaglandins. Since prostaglandins are key mediators of the inflammatory and pain response, reducing their synthesis is the foundational action through which Diclosin provides symptomatic relief from pain and swelling.

3. Available Preparations and Routes of Administration

The Diclofenac active ingredient is widely utilized and formulated into several key pharmaceutical preparations, which include oral tablets (such as delayed-release forms), topical gels, and specialized forms like injectable solutions. This spectrum of preparations allows for therapeutic flexibility.

These forms dictate the route of administration, enabling either systemic or local action. Oral tablets provide a systemic effect, circulating the drug throughout the body, whereas a topical gel preparation facilitates highly localized delivery of Diclofenac directly to an application area for concentrated action.

Regulatory References

  1. MedlinePlus

What side effects are possible with Diclosin?

Possible Side Effects and Safety Information

Diclosin is associated with serious, well-documented safety risks, primarily impacting the cardiovascular and gastrointestinal systems, which are common to the class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Serious Cardiovascular and Thrombotic Risk

The use of systemic Diclosin carries an increased risk of serious arterial thrombotic events, including myocardial infarction (heart attack) and stroke. This risk may be similar to that observed with selective COX-2 inhibitors and is considered to be dose- and duration-dependent. The risk is higher for long-term treatment and high daily doses. Diclosin is generally not recommended for patients with established heart failure (NYHA class II-IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease. Pre-existing cardiovascular risk factors (e.g., high blood pressure, diabetes, smoking) require careful consideration before treatment initiation.

Gastrointestinal Risk

All systemic NSAIDs, including Diclosin, can cause serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines. These events can occur at any time during treatment, often without warning symptoms, and can be fatal. Elderly patients and those with a history of GI disease are at an increased risk.

Other Adverse Reactions and Safety Cautions

Commonly reported side effects include gastrointestinal upset, headache, and dizziness. Less commonly, serious reactions have been documented, including severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), serious liver injury (hepatotoxicity), and hypersensitivity reactions such as anaphylaxis. Patients with risk factors for renal impairment should be monitored. Treatment should utilize the lowest effective dose for the shortest possible duration to minimize the potential for serious risks.

Overdose and Emergency Response

The official regulatory profile for Diclosin (Diclofenac) overdose is defined by specific clinical manifestations and mandated emergency actions, based on authoritative government documentation.

Documented Overdose Manifestations

Overdose may initially present with common gastrointestinal signs, including nausea, vomiting, and epigastric pain. Central nervous system effects such as headache, drowsiness, dizziness, and tinnitus are also documented as clinical manifestations. In severe cases, the official profile cites the potential for acute organ system toxicity, specifically acute renal failure and hepatic failure, alongside severe neurological disturbances such as convulsions and coma. Serious consequences, including severe gastrointestinal bleeding, are noted to carry elevated risks in the elderly population. Convulsions may be a predominant feature in pediatric patients.

Emergency Action and Supportive Management

Official guidance mandates that individuals seek immediate medical attention right away if an overdose is suspected or has occurred. The required action involves contacting emergency services or a poison control center for instructions. Regulatory information confirms that no specific antidote is known for this NSAID, making management entirely reliant on symptomatic and supportive treatment. This involves close medical monitoring of vital signs and laboratory parameters, with observation of renal and hepatic function being a standard procedural requirement in the official context of overdose management.

Therapeutic Uses of Diclosin

Diclosin (Diclofenac) is primarily used for its supportive therapeutic benefit across domains involving heightened symptomatic discomfort, offering symptomatic relief to help patients cope more steadily with difficult episodes. It is commonly used for the relief of pain, tenderness, swelling, and stiffness caused by various inflammatory conditions.


Symptomatic Relief for Chronic Joint Inflammation

Diclosin is commonly used across conditions characterized by periods of heightened symptoms related to inflammatory or irritative states, such as Osteoarthritis and Rheumatoid Arthritis. The medication helps address symptom clusters that may become intense or disruptive, including persistent joint pain, swelling, and stiffness. It contributes to improved comfort during symptomatic periods and helps maintain a sense of stability when symptoms are more noticeable. Diclosin is generally used for conditions involving recurrent or episodic manifestations of pain and inflammation, including Ankylosing Spondylitis, Migraine attacks, and Primary Dysmenorrhea.


Management of Acute Pain and Injury Discomfort

This medication is applied in clinical settings that involve acute or unstable symptom patterns from various sources. It is relevant when supportive symptom management is appropriate for acute pain from musculoskeletal injuries like sprains and strains, and for post-procedural discomfort. It provides supportive relief when symptoms interfere with routine activities, and assists with easing symptoms that interfere with daily functioning during these temporary phases. It is also commonly used to help with general symptoms related to systemic imbalance, by addressing fever and generalized body aches.

“The medication may be part of a symptomatic management strategy relevant for easing distressing symptoms, supporting the patient through difficult episodes.”


Quick Fact: Relief for Joint Pain, Swelling, and Fever (The medication helps manage a cluster of symptoms associated with inflammatory responses.)

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility and Contraindications for Diclosin (Diclofenac)

Official regulatory guidelines define strict criteria for who can and cannot use the Nonsteroidal Anti-inflammatory Drug (NSAID), Diclosin.

Populations That Must NOT Use Diclosin (Contraindicated)

Use is absolutely prohibited for patients with specific high-risk conditions, including:

  • A known allergy or severe reaction (e.g., asthma, urticaria) to aspirin or other NSAIDs.
  • Active or recurrent history of peptic ulceration or gastrointestinal (GI) bleeding.
  • Severe impairment of kidney (renal) or liver (hepatic) function.
  • Established congestive heart failure (NYHA Class II-IV) or established ischemic heart disease (for systemic use).
  • Use in the setting of coronary artery bypass graft (CABG) surgery.
  • Women who are in the third trimester of pregnancy.

Restricted and Age-Related Eligibility

Population Group Eligibility Status
Older Adults (Geriatric) Eligible, but use requires caution and the lowest effective dose due to increased risk of serious adverse events.
Children Systemic use is not established or not recommended for children under 14 years of age for many standard indications.
Pregnancy Contraindicated in the third trimester; not recommended in the first and second trimesters.

Use is also conditional and requires close medical supervision for patients with conditions such as mild-to-moderate organ impairment, uncontrolled hypertension, or a history of GI disorders.

What should I know about interactions with other medicines?

Diclosin Interactions with other medicines and products

The official regulatory profile for Diclosin (Diclofenac) establishes specific interaction patterns and use restrictions. The medicine is contraindicated for the treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other systemic NSAIDs is generally not recommended due to the documented potential for additive adverse effects.


Official Pharmacokinetic and Pharmacodynamic Statements

The medicine's interaction structure is formally defined by effects on drug exposure and pharmacodynamic risk.

  • Exposure Modification: Co-administration with strong CYP inhibitors, such as Voriconazole, causes a significant pharmacokinetic interaction, resulting in a labeled increase in Diclosin's plasma concentration. Diclosin can also increase the serum concentration and prolong the half-life of Digoxin.
  • Additive Risk: Concurrent use with Anticoagulants, Anti-platelet Agents, Systemic Corticosteroids, and SSRIs is documented to carry an increased risk of ulceration or bleeding.
  • Efficacy Reduction: Diclosin may decrease the efficacy of co-administered Diuretics, ACE Inhibitors, and Angiotensin II Antagonists, with concern documented for the potential progression of renal function deterioration in vulnerable patients.
  • Administration Constraints: For certain oral formulations, taking the medicine with food is documented to reduce effectiveness, establishing an official requirement to take it on an empty stomach. Alcohol consumption is listed as a factor that increases the risk for gastrointestinal bleeding.

Interaction Context

Elderly patients are documented to have a greater risk for serious gastrointestinal adverse events. Caution is also formally required in patients with impaired cardiac or renal function when co-administering with other medicinal products that affect renal function.

Mechanism of Action

How Diclosin Works


Modulation of Prostaglandin Synthesis via COX Inhibition

Diclosin (Diclofenac) exerts its primary mechanism by acting as a competitive inhibitor of Cyclooxygenase (COX) enzymes, particularly the inducible COX-2 isoform. This targeted action interrupts the conversion of Arachidonic Acid into Prostaglandins—key lipid mediators that facilitate signaling in inflammatory pathways. The resulting suppression of PGE2 production leads to a reduction in chemical signaling that sensitizes peripheral nociceptors and influences key inflammatory pathways.


Direct Neural and Central Pathway Engagement

The mechanism also involves non-COX actions, including the direct blockade of voltage-dependent sodium channels in peripheral nerve fibers, which helps stabilize the neuronal membrane. Furthermore, the drug's inhibition of PGE2 synthesis in the hypothalamus allows the central thermoregulatory set point to reset. These complementary actions modulate both peripheral nerve excitability and central thermoregulation, which influence downstream physiological outcomes.

Dosage and Administration Information

How to Use Diclosin

Diclosin (Diclofenac) is administered through several official routes including oral (swallowing tablets or solution), topical (application to the skin), intramuscular injection, and intravenous infusion. These diverse formulations allow for either a systemic effect (oral, injectable) or a localized effect (topical, ophthalmic).

Official Dosing and Administration

Official dosing is determined by the specific condition being addressed, always adhering to the principle of using the lowest effective dose for the shortest duration possible. For most chronic conditions like Osteoarthritis, the typical oral maintenance dose is often within the range of 50 mg two or three times daily, or 75 mg twice daily for modified-release forms, with a maximum systemic daily dose generally not exceeding 150 mg.

Dosing frequency is generally defined as divided doses (e.g., two to four times daily) for immediate-release oral tablets to maintain consistent systemic levels, whereas extended-release formulations are typically taken once daily.

Formulation-Specific Requirements

The way Diclosin is taken depends heavily on the formulation, in accordance with product labeling. Delayed-release (DR) and extended-release (ER) tablets must be swallowed whole and should not be crushed, chewed, or split, as this would compromise the intended release profile. Specific oral powder formulations must be fully dissolved in water and consumed immediately, often on an empty stomach. Injectable forms are generally reserved for acute, short-term pain in a supervised setting and are restricted to a brief course, with transition to oral therapy recommended as soon as possible.

Recent Clinical Evidence

Diclosin: Recent Clinical Evidence

Research evidence for Diclosin (a nonsteroidal anti-inflammatory drug) focuses on its use in managing symptoms of inflammatory conditions, primarily rheumatoid arthritis (RA) and osteoarthritis (OA).


Evidence for Acute Relief

Clinical trials have evaluated the short-term use of Diclosin for acute pain and symptom relief. Short-term randomized, controlled trials (RCTs) assessed outcomes over periods such as two weeks, focusing on standardized pain scales and joint tenderness.

  • Onset of Action: Assessments in some studies were conducted on the onset of symptom relief, with results observed within the first hour for certain formulations.
  • Key Outcomes: The primary outcomes in these trials focused on quantifying changes in joint pain, swelling, and patient global assessment scores when compared with a placebo.

Evidence for Chronic Management

Longer-term research has examined the chronic use of Diclosin, often over periods of six months to one year, in participants with established RA or OA.

  • Symptom Changes: Studies explored changes in measures of disease activity, such as the Disease Activity Score 28 (DAS28), to evaluate the impact on established symptoms, including morning stiffness and functional limitations.
  • Combination Use: Research has also evaluated whether using Diclosin alongside other established disease-modifying antirheumatic drugs (DMARDs) affects overall symptom management outcomes.

Safety and Tolerability Profile

A pooled analysis of multiple RCTs summarized the reported safety profile. The occurrence of reported adverse events is closely monitored due to the nature of this class of medication.

Adverse Event Category Frequently Reported Events in Studies
Gastrointestinal (GI) Dyspepsia, nausea, abdominal pain
Hepatic Elevations in liver enzyme values (reversible)

Adverse events reported in the studies were generally classified as mild to moderate. Long-term treatment trials include routine monitoring of liver function tests (e.g., ALT/AST) and assessment for GI side effects. Epidemiological data suggest an association between long-term, high-dose use of oral Diclosin and an increased risk of serious cardiovascular events.

Key Studies & References

  1. Safety review of diclofenac - Therapeutic Goods Administration (TGA) (Regulatory Safety Document)
  2. Efficacy of ultramicronised diclofenac in patients with osteoarthritis – systematic review with network meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Diclosin (FAQ)

Q: How quickly does Diclosin typically start working?

A: Studies and official information indicate that relief from certain oral forms of Diclosin may begin within the first hour of administration. However, the time it takes for the full intended effect to be noticeable can vary, depending on the specific formulation being used, such as with topical gels, which may require several days of consistent use.


Q: How long can a person generally take Diclosin for?

A: Regulatory guidance advises using Diclosin for the shortest duration possible at the lowest effective dose. While it may be used long-term for chronic conditions like arthritis, official warnings note that prolonged or high-dose systemic use is associated with a greater risk of serious side effects.


Q: Is it common for Diclosin to cause stomach issues?

A: Mild stomach issues, such as stomach upset, nausea, and abdominal pain, are among the commonly reported side effects in clinical studies. It is noted in official documents that medicines in this class (NSAIDs) are associated with a documented risk of serious gastrointestinal events, such as bleeding or ulcers.


Q: Can Diclosin affect blood pressure levels?

A: Yes, official warnings state that NSAIDs, including Diclosin, can cause a new onset of hypertension (high blood pressure) or worsening of pre-existing hypertension. Official documents suggest that blood pressure monitoring may be necessary during treatment.


Q: What should I do if I forget to take a dose of Diclosin?

A: Official drug information suggests that if a regular dose is missed, it may be taken when remembered. However, if it is nearly time for the next scheduled dose, the missed dose is typically skipped to avoid taking two doses close together and continue with the regular schedule.


Q: Are there any specific foods or drinks to avoid while taking Diclosin?

A: Regulatory documents explicitly state that alcohol consumption increases the risk of gastrointestinal bleeding. Therefore, the use of alcohol during treatment is noted in official documents as generally being discouraged. No general restriction on specific foods is listed.


Q: Is Diclosin known to cause drowsiness or affect alertness?

A: Yes, regulatory documents list side effects such as dizziness, drowsiness, and somnolence (sleepiness) as possible adverse reactions to the medicine. Regulatory warnings mention that if these effects occur, activities such as driving or operating machinery may need to be avoided.


Q: How is Diclosin typically eliminated from the body?

A: Diclosin is processed primarily by the liver through metabolism. The resulting inactive metabolites are then largely eliminated from the body via the urine (kidneys), with a smaller portion excreted through the bile.


Q: What if I experience mild swelling while using Diclosin?

A: Swelling, particularly in the feet, ankles, or hands (known as edema), has been reported as a side effect. Official documents note that swelling can also be a sign of a more serious underlying condition, such as heart failure, which is addressed under medical supervision.


Q: Is Diclosin considered a narcotic or opioid?

A: No, Diclosin is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is a non-narcotic, non-opioid medicine and acts by interrupting the body's inflammatory process.


Q: Are there different strengths or formulations of Diclosin?

A: Yes, Diclosin is available in various official forms, including immediate-release and delayed-release oral tablets, powder for oral solution, topical gels, and injectable solutions. Common oral strengths listed in dosing guides can include 25 mg, 50 mg, 75 mg, and extended-release 100 mg.


Q: Is Diclosin available without a prescription in some places?

A: While the oral forms of Diclosin generally require a prescription, some lower-strength topical gel formulations have been approved for over-the-counter (OTC) sale in certain regions. The availability is determined by local regulatory approval.


Q: Does taking Diclosin affect lab test results, such as for blood work?

A: Diclosin is documented to cause temporary elevations in liver enzyme values, which are detected in blood tests. Regulatory documents mention that routine monitoring of liver function tests is sometimes conducted during prolonged treatment.


Q: Can Diclosin make a person more sensitive to the sun?

A: Increased sensitivity of the skin to sunlight, known as a photosensitivity reaction, has been reported as a possible adverse reaction to Diclosin, especially when using the topical gel formulation.


Q: Is it true that Diclosin can affect kidney function over time?

A: Regulatory warnings indicate that long-term use of NSAIDs like Diclosin may lead to renal injury and could potentially worsen pre-existing kidney impairment. Official documents advise that using the lowest effective dose for the shortest time is generally practiced to minimize this potential risk.


Q: What are the signs of a serious skin reaction to Diclosin?

A: Serious skin reactions are rare, but symptoms suggesting one should be immediately addressed by a healthcare professional. Signs can include a rash combined with fever or flu-like symptoms, blistering or peeling of the skin, or a red rash accompanied by swelling of the face or lymph nodes (e.g., Stevens-Johnson syndrome).


Q: Is Diclosin a long-term or short-term treatment?

A: Diclosin is used for both short-term relief of acute pain and long-term management of chronic conditions, such as arthritis. Due to documented safety risks, official guidance emphasizes using the medicine only as needed, at the lowest dose, and for the shortest duration necessary.


Q: Does Diclosin interact with herbal supplements like St. John's Wort?

A: Official information generally notes that there is limited data on the safety of using all herbal remedies or supplements alongside Diclosin. This is because these products are not always routinely evaluated for their potential interactions with prescription medicines in regulatory filings.


Q: Is there a risk of dependence or addiction with Diclosin?

A: No, official classifications confirm that Diclosin is not an opioid or narcotic. As such, there is no documented risk of dependence or addiction associated with its use.


Q: What happens if I accidentally take more Diclosin than recommended?

A: Taking more than the recommended dose can increase the likelihood of side effects, such as drowsiness, stomach pain, vomiting, or diarrhea. Symptoms of overdose are a serious safety concern and typically require immediate professional medical assessment.


Q: Are there specific instructions for driving while taking Diclosin?

A: Official warnings state that if Diclosin causes effects like dizziness, tiredness, or vision changes, it is advised that activities such as driving or operating machinery may need to be avoided. This caution remains until the side effects have passed.


Q: Can Diclosin be used for migraine headaches?

A: Yes, specific forms of Diclosin, such as the oral powder for solution, have received official indication for the acute treatment of migraine attacks, with or without aura.


Q: Are there different salts or forms of Diclosin mentioned in official sources?

A: Yes, the active ingredient Diclofenac is commonly supplied as two main pharmaceutical salts: Diclofenac Sodium and Diclofenac Potassium. These different forms can influence factors like the rate at which the medicine is absorbed.


Q: Is it possible to be allergic to Diclosin?

A: Yes, official product information indicates that Diclosin is contraindicated (must not be used) in patients with a known allergy or severe hypersensitivity reaction to Diclofenac or any components of the drug.


Q: Does Diclosin need to be taken with food?

A: The requirement depends entirely on the specific product formulation. Some forms must be taken on an empty stomach to ensure full absorption and effectiveness, while other forms may be taken with food to potentially help reduce stomach upset.


Q: Why is Diclosin sometimes combined with another medicine in a single pill?

A: Diclosin is sometimes combined in a single pill with a second agent, such as misoprostol, primarily to provide gastroprotection. This combination is designed to help reduce the documented risk of stomach ulcers and gastrointestinal bleeding associated with long-term NSAID use.


Q: Is it safe to drink a small amount of alcohol while on Diclosin?

A: Official product information lists alcohol as a factor that increases the risk for gastrointestinal bleeding. Therefore, the consumption of alcohol while undergoing treatment with Diclosin is generally noted in official sources as being discouraged.


Q: How can I tell if a side effect is serious and requires immediate attention?

A: Signs of a serious side effect can include unexplained shortness of breath, sudden swelling of the face or throat, chest pain, or signs of internal bleeding such as black or tarry stools or vomiting material that looks like coffee grounds. Any of these signs should be promptly assessed by a healthcare professional.

How should Diclosin be stored and disposed of?

How to Store and Dispose of Diclosin?

Category Official Regulatory Statement
Storage Temperature Oral Forms: Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), not exceeding 30 C. Injection: Store below 30 C.
Protection Requirements Protect the medication from moisture and light. Diclofenac ampoules must not freeze.
Container & Stability Keep the product in its original, tightly closed container. Prepared intravenous infusion solutions must be used immediately and should not be stored.
Child Safety The medicine must be kept out of the sight and reach of children and pets and stored in a secure, safe place.
Disposal Instructions Dispose of the product in accordance with all local and national regulations. Used transdermal patches must be folded adhesive-sides together before being discarded.
Environmental Rules The best method is an authorized drug take-back program. The product should generally not be disposed of via wastewater or household trash unless following specific instructions for mixing with an undesirable substance.

These instructions outline mandatory environmental constraints and container rules necessary to preserve the product's integrity and ensure safe handling and disposal as defined by regulatory bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diclosin found in:

A-Z Index: